GlaxoSmithKline News and Research

RSS

Research report on sports nutrition market in Europe

Sports Nutrition Market in Europe 2014-2018 has been prepared based on an in-depth market analysis with inputs from industry experts.

31 May 2014

Novozymes Biopharma to assess novel subunit vaccine candidate using Veltis technology

Novozymes Biopharma has entered a new collaborative research agreement with one of the world’s top vaccine companies. The partnership will enable the company to evaluate Novozymes Biopharma's modified recombinant human albumin (rAlbumin) Veltis technology, to assess the dosing and performance of a novel subunit antigen vaccine candidate.

30 May 2014

Mylan launches generic version of GlaxoSmithKline's Malarone Tablets

Mylan Inc. today announced that it has launched Atovaquone and Proguanil Hydrochloride Tablets, 62.5 mg/25 mg and 250 mg/100 mg, the generic version of GlaxoSmithKline's Malarone® Tablets.

29 May 2014

UK opens criminal inquiry into Glaxosmithkline business practices

The British drug maker GlaxoSmithKline said late Tuesday that the Serious Fraud Office of Britain had opened a formal criminal investigation into its "commercial practices." Neither GlaxoSmithKline nor the fraud office provided further details about what practices were being investigated. .

29 May 2014

First Edition: May 28, 2014

Today's early morning highlights from the major news organizations, including reports about efforts to cut back spending on cancer care and the ouster of a key Army hospital administrator.

28 May 2014

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

A drug's half-life indicates how long a substance will remain active in the body. It is essentially the period of time that it takes for the concentration of the amount of the drug to be reduced by half, and therefore, determines how frequently a drug needs to be administered to maintain its therapeutic effect.

27 May 2014

The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca

Quoting Mike Snowden (VP & Head of Discovery Sciences, AstraZeneca), “it’s where biology meets chemistry”. It’s where for the first time a target protein can be probed for novel molecules that modulate its function, of course we want to do this to prove a hypothesis that these proteins are drug targets with the potential to deliver innovative medicines.

20 May 2014

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

GlaxoSmithKline plc today presented data at the American Thoracic Society (ATS) from a late-stage clinical study.

20 May 2014

TCM announces winners of 26th Annual Industry Awards

The Tech Council of Maryland (TCM), Maryland's largest technology trade association for life science and technology, today announced the winners of its 26th Annual Industry Awards.

16 May 2014

Isis Pharmaceuticals receives $3 million milestone payment from GSK

Isis Pharmaceuticals, Inc. announced today that it has earned a $3.0 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a natural history study, which will support the advancement of one of the alliance programs.

15 May 2014

Metabolon, GSK sign research collaboration agreement

Metabolon, Inc., a leading diagnostics and research services company offering metabolomics research platforms, has entered into a collaboration with GlaxoSmithKline to provide metabolomic profiling services and to collaborate on other research projects leveraging Metabolon's leading DiscoveryHD4 platform.

14 May 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates.

7 May 2014

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Lipids, primarily cholesterol and triglycerides, come from two sources: what is naturally manufactured in the liver and what comes from the intestines through the diet.

From Sanofi 7 May 2014

GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

GlaxoSmithKline plc and Theravance, Inc. today announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder), the first once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of chronic obstructive pulmonary disease (COPD), is now available to retail pharmacies in the US.

28 Apr 2014

FDA grants marketing approval to GlaxoSmithKline's diabetes drug based on Novozymes' Veltis technology

The US Food and Drug Administration has granted marketing approval to GlaxoSmithKline's new type 2 diabetes drug, branded Tanzeum in the US and Eperzan in Europe, which uses Novozymes' Veltis technology to achieve an extended half-life that means patients are only required to inject their medication once a week.

25 Apr 2014

Targeting B cells may help reduce disease activity for people with multiple sclerosis

A new study suggests that targeting B cells, which are a type of white blood cell in the immune system, may be associated with reduced disease activity for people with multiple sclerosis (MS).

25 Apr 2014

Sales of hepatitis drug shatter records

Record sales of the pricey new drug, Sovaldi, pushed first-quarter earnings of Gilead Sciences beyond expectations. Meanwhile, Novartis' recently announced deals with GlaxoSmithKline and Eli Lilly show manufacturers' swing towards specialization, reports The Wall Street Journal.

25 Apr 2014

Novartis to buy Glaxosmithkline's oncology unit

The deal, worth billions, will also see Novartis sell its vaccines unit to Glaxo and partner with Glaxo on their consumer divisions. Novartis also said it will sell its animal health division to Eli Lily.

23 Apr 2014

First Edition: April 22, 2014

Today's early morning highlights from the major news organizations, including marketplace news about the Novartis purchase of GlaxoSmithKline's oncology unit for $14.5 billion.

22 Apr 2014

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

21 Apr 2014

GlaxoSmithKline News and Research

Research report on sports nutrition market in Europe

Novozymes Biopharma to assess novel subunit vaccine candidate using Veltis technology

Mylan launches generic version of GlaxoSmithKline's Malarone Tablets

UK opens criminal inquiry into Glaxosmithkline business practices

First Edition: May 28, 2014

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

TCM announces winners of 26th Annual Industry Awards

Isis Pharmaceuticals receives $3 million milestone payment from GSK

Metabolon, GSK sign research collaboration agreement

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

FDA grants marketing approval to GlaxoSmithKline's diabetes drug based on Novozymes' Veltis technology

Targeting B cells may help reduce disease activity for people with multiple sclerosis

Sales of hepatitis drug shatter records

Novartis to buy Glaxosmithkline's oncology unit

First Edition: April 22, 2014

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News